Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tak-928

Phase 3

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

IO-Resistant SqnsclcRecruiting

IO-Resistant SqnsclcPhase 3

Recruiting

Timeline

Expected Milestones

Q4 2029

Phase 3Recruiting

IO-Resistant Sqnsclc

NCT07217301

Clinical

Trials by Indication[1]

IO-resistant sqNSCLC1 trial

A Randomized, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Recruiting·FFortvita Biologics (USA)Inc.·Phase 3·NCT07217301·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tak-928. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Tak-928. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Takeda

Related News